Patent intelligence · US
US 10463029
Rodent model of steel syndrome
Rodent model of steel syndrome
Patent details — US 10463029
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 5, 2019
- Expiration
- Oct 31, 2039
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Claims
- 13
- CPC classes
- A61K, A61K49/0008
Quick answer
US 10463029 (Rodent model of steel syndrome) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Nov 5, 2019. Expires Oct 31, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K49/0008
More from REGENERON PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421512
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted -
US 12421317
Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies
granted -
US 12421315
CLL-1 targeted immunotherapies
granted -
US 12419963
Diels-Alder conjugation methods
granted -
US 12415856
EGFR x CD28 multispecific antibodies
granted -
US 12410442
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
granted -
US 12404505
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
granted -
US 12402611
Genetically modified mice and engraftment
granted
Frequently asked questions
What is US patent 10463029?
US 10463029 (Rodent model of steel syndrome) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Nov 5, 2019. Expires Oct 31, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10463029?
REGENERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 837 pharmaceutical patents for this assignee.
When does US 10463029 expire?
Our index shows an expiration date of Oct 31, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.